Last €13.34 EUR
Change Today +0.10 / 0.76%
Volume 0.0
NPW1 On Other Exchanges
New York
As of 2:06 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (NPW1) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/5/14 - €13.93
52 Week Low
09/2/13 - €8.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SMITH & NEPHEW PLC (NPW1)

Related News

No related news articles were found.

smith & nephew plc (NPW1) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (NPW1) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopaedic reconstruction implants for hip, knee, and shoulder joints; and ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides sports medicine products, which offer surgeons an array of instruments, technologies, and implants to perform minimally invasive surgery of the joints, including knee, hip, and shoulder repair; and trauma and extremities products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilization of fractures and deformity correction procedures. In addition, this segment provides arthroscopy enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, as well as offers radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissues to healthcare providers. The company’s Advanced Wound Management segment offers a range of initial wound bed preparation and full wound closure products. Its products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers; and products for the treatment of wounds, such as burns and invasive surgery. Smith & Nephew plc primarily serves medical and surgical treatments and service providers. The company was founded in 1856 and is headquartered in London, the United Kingdom.

11,000 Employees
Last Reported Date: 05/1/14
Founded in 1856

smith & nephew plc (NPW1) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $4.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.

smith & nephew plc (NPW1) Key Developments

Smith & Nephew Appoints KPMG LLP as Auditor

Smith & Nephew announced the appointment of KPMG LLP (KPMG) as its auditor for the year ending December 31, 2015, subject to approval by shareholders at the 2015 Annual General Meeting.

Smith & Nephew Enters Commercial Agreement to Bring Robotic Navigation to JOURNEY UNI Knee Procedure

Smith & Nephew announced a new commercial agreement with Blue Belt Technologies. Under this agreement, surgeons using the Navio system will be able to implant Smith & Nephew's JOURNEY(TM) UNI partial knee. The Navio System provides surgeons with precise surgical planning and handheld robotic-controlled bone preparation for use with partial knee replacements. Through its advanced, intraoperative navigation, the system guides the surgeon in optimally placing the implant and balancing the knee in order to deliver consistent results. And, from a cost-savings perspective, the Navio System does not require the added time and expense of preoperative CT images and is less than half the cost of its leading competitor.

Smith & Nephew Announces Temporarily Cease of Commercial Distribution of the RENASY Negative Pressure Wound Therapy Product Line in the United States

Smith & Nephew has temporarily ceased commercial distribution of the RENASYS Negative Pressure Wound Therapy product line in the United States. This action follows instruction from the FDA to obtain new regulatory clearances through the premarket notification (510K) process in respect of certain design enhancements made to RENASYS systems. The applications for clearance have now been filed and are awaiting action. This action only affects RENASYS products in the United States. Other NPWT products, including PICO(TM), Smith & Nephew's portable, canister-free system, are not affected. Smith & Nephew is working cooperatively with the FDA to address its concerns in order to resume distribution of RENASYS products in the United States as soon as possible and regrets any disruption caused to customers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPW1:GR €13.34 EUR +0.10

NPW1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.26 USD +0.24
Coloplast A/S kr477.50 DKK -1.10
CR Bard Inc $146.95 USD +1.12
St Jude Medical Inc $67.03 USD -0.03
Zimmer Holdings Inc $99.82 USD -3.34
View Industry Companies

Industry Analysis


Industry Average

Valuation NPW1 Industry Range
Price/Earnings 28.7x
Price/Sales 3.7x
Price/Book 3.8x
Price/Cash Flow 28.4x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at